Drug shows potential for people with mild Alzheimer’s disease

Solanezumab, an experimental Alzheimer’s drug, did not slow mental decline in each of two phase 3 clinical trials, but a positive effect was seen when data from both studies was combined. Drug maker Eli Lilly & Co. said that combining the results of the two trials showed a 34 percent slowing of mental decline for people with mild Alzheimer’s who took solanezumab compared to those taking a placebo. While more research is needed, the results suggest that a therapy targeting beta amyloid can have a beneficial effect on cognitive abilities in people with Alzheimer’s.
Read the article >>

http://consumer.healthday.com/Article.asp?AID=669437

http://www.optimumseniorcare.com/services/alzheimerscare.php